--- title: "A Look At Viatris (VTRS) Valuation After UBS Upgrade And Raised Price Target" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/275782686.md" description: "Viatris (VTRS) has gained investor attention following a UBS upgrade and management changes, with a 90-day share price return of 47.85%. UBS raised its price target to $18, while the stock is considered overvalued at $16.13 compared to a fair value of $12.67. The company aims to improve margins through higher-margin products, but risks remain from price pressures on generics. Despite being flagged as overvalued, Viatris' P/S ratio of 1.3x is lower than industry peers, suggesting potential misalignment between sentiment and fundamentals." datetime: "2026-02-12T16:12:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275782686.md) - [en](https://longbridge.com/en/news/275782686.md) - [zh-HK](https://longbridge.com/zh-HK/news/275782686.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275782686.md) | [English](https://longbridge.com/en/news/275782686.md) # A Look At Viatris (VTRS) Valuation After UBS Upgrade And Raised Price Target Viatris (VTRS) has been back on investors’ radar after UBS shifted to a more positive stance on the stock. This move coincides with management changes and ongoing global expansion efforts. See our latest analysis for Viatris. The UBS upgrade and management reshuffle come on top of a sharp rebound in sentiment, with Viatris’ 90-day share price return of 47.85% and 1-year total shareholder return of 59.90% pointing to momentum that has recently picked up. If this renewed interest in healthcare names has you looking wider, it could be a good moment to scan our 25 healthcare AI stocks as potential next ideas to research. With the share price rallying, UBS lifting its target to US$18, and an intrinsic value estimate implying a large discount, the key question now is whether Viatris still trades below its fundamentals or if the market is already pricing in future growth. ## Most Popular Narrative: 27.3% Overvalued Compared with the most followed narrative fair value of about $12.67, Viatris at $16.13 is framed as fully valued and then some, setting up a valuation built on improving margins and future profitability. > _Progress in developing and launching higher-margin complex generics, biosimilars, and innovative branded products (e.g., fast-acting meloxicam, ophthalmology assets) will improve gross margins and stabilize earnings by reducing exposure to price-sensitive, low-margin basic generics._ _Read the complete narrative._ Curious what kind of revenue profile, margin lift, and earnings path are needed to support this richer valuation? The narrative leans on ambitious profit recovery, a step change in profitability, and a premium future earnings multiple more often associated with faster growing sectors. The real question is how those moving parts fit together over the next few years. **Result: Fair Value of $12.67 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the risk that ongoing price pressure on mature generics or integration setbacks at key facilities could limit the profit recovery story. Find out about the key risks to this Viatris narrative. ## Another Lens: Multiples Point to Deep Discount While the popular narrative flags Viatris at about 27.3% overvalued versus a US$12.67 fair value, the current P/S of 1.3x looks far lower than peers at 3.9x and the industry at 4.3x, and below a fair ratio of 3.6x. Is sentiment out of sync with the numbers? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:VTRS P/S Ratio as at Feb 2026 ## Build Your Own Viatris Narrative If you are not fully on board with this view or prefer to test your own assumptions against the numbers, you can build a tailored thesis in just a few minutes. To get started, use Do it your way. A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. ## Looking for more investment ideas? If Viatris has sharpened your focus, do not stop here, use the screener to line up your next set of quality ideas before others move first. - Target value opportunities by reviewing 51 high quality undervalued stocks that pair solid financial profiles with prices that may not fully reflect their fundamentals yet. - Prioritise resilience with 85 resilient stocks with low risk scores, highlighting companies that score well on stability so you are not relying on luck when conditions get tougher. - Get an early look at potential future leaders via our screener containing 24 high quality undiscovered gems, focusing on lesser known names with fundamentals you can actually scrutinise. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### 相關股票 - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [Viatris (VTRS.US)](https://longbridge.com/zh-HK/quote/VTRS.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) ## 相關資訊與研究 - [Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research](https://longbridge.com/zh-HK/news/278908205.md) - [A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review](https://longbridge.com/zh-HK/news/277640565.md) - [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-HK/news/278566951.md) - [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/zh-HK/news/278917368.md) - [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-HK/news/278448836.md)